Serotonin syndrome—A focused review
Basic & Clinical Pharmacology & Toxicology · 2023-08 · 133 (2) · 124-129
DOI: 10.1111/bcpt.13912 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, online erschienen am 20.06.2023. Verfasst von Nicolaj Mikkelsen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Serotonin Syndrome, Mental Disorders. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Serotonin syndrome is a potentially life‐threatening syndrome with manifestations spanning from mild adverse effects to life‐threatening toxicity. The syndrome is caused by overstimulation of serotonin receptors by serotonergic drugs. Since the use of serotonergic drugs is increasing, primarily due to the widespread use of selective serotonin reuptake inhibitors, cases of serotonin syndrome have likely seen a parallel increase. The true incidence of serotonin syndrome remains unknown due to its diffuse clinical presentation.
Objectives
This review aims to provide a clinically focused overview of serotonin syndrome, covering its pathophysiology, epidemiology, clinical manifestations, diagnostic criteria, differential diagnosis and treatment, as well as classifying serotonergic drugs and their mechanism of action. The pharmacological context is emphasized, as it is crucial for the detection and management of serotonin syndrome.
Methods
Focused review based on a literature search using the PubMed database. Findings and conclusion Serotonin syndrome can occur through therapeutic use or overdose of a single serotonergic drug or as a drug interaction between two or more serotonergic drugs. Central clinical features consist of neuromuscular excitation, autonomic dysfunction and altered mental status, occurring in a patient undergoing new or altered serotonergic therapy. Early clinical recognition and treatment are crucial to prevent significant morbidity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark.
- Department of Clinical Research, Faculty of Health Science, University of Southern Denmark, Odense, Denmark.
ORCID-Profile: Nicolaj Mikkelsen, Per Damkier, Sidsel Arnspang Pedersen
Zitieren
APA
Mikkelsen, N., Damkier, P., & Pedersen, S. A. (2023). Serotonin syndrome—A focused review. Basic & Clinical Pharmacology & Toxicology, 133(2), 124-129. https://doi.org/10.1111/bcpt.13912
Vancouver
Mikkelsen N, Damkier P, Pedersen SA. Serotonin syndrome—A focused review. Basic & Clinical Pharmacology & Toxicology. 2023;133(2):124-129. doi:10.1111/bcpt.13912
BibTeX
@article{Mikkelsen2023,
author = {Mikkelsen, Nicolaj and Damkier, Per and Pedersen, Sidsel Arnspang},
title = {Serotonin syndrome—A focused review},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2023},
volume = {133},
number = {2},
pages = {124--129},
doi = {10.1111/bcpt.13912}
}
EUVIMED